Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Phase I study of weekly cisplatin, bolus fluorouracil and escalating doses of irinotecan in advanced solid tumors.

Ku GY, O'Reilly EM, Saltz LB, Schrag D, Maki RG, Kelsen DP, Ilson DH.

Cancer Invest. 2009 May;27(4):402-6. doi: 10.1080/07357900802406327.

PMID:
19219674
2.

A weekly 24-h infusion of high-dose 5-fluorouracil (5-FU)+leucovorin and bi-weekly cisplatin (CDDP) was active and well tolerated in patients with non-colon digestive carcinomas.

Caroli-Bosc FX, Van Laethem JL, Michel P, Gay F, Hendlisz A, Forget F, Bleiberg H.

Eur J Cancer. 2001 Oct;37(15):1828-32.

PMID:
11576835
4.

Phase I study of capecitabine in combination with cisplatin and irinotecan in patients with advanced solid malignancies.

Sayar H, Shen Z, Lee SJ, Royce M, Rabinowitz I, Lee F, Smith H, Eberhardt S, Maestas A, Lu H, Verschraegen C.

Invest New Drugs. 2009 Apr;27(2):153-8. doi: 10.1007/s10637-008-9172-x. Epub 2008 Sep 5.

PMID:
18773144
5.

Treatment of advanced digestive non-colon cancer with a weekly 24-h infusion of high-dose 5-fluorouracil modulated by folinic acid and cisplatin: an easy-to-use and well-tolerated combination.

Delaunoit T, Maréchal R, Hendlisz A, Eisendrath P, Legendre H, Pector JC, De Becker D, Bleiberg H.

Anticancer Drugs. 2004 Aug;15(7):725-8.

PMID:
15269605
6.
7.

A phase I, dose-finding study of irinotecan (CPT-11) short i.v. infusion combined with fixed dose of 5-fluorouracil (5-FU) protracted i.v. infusion in adult patients with advanced solid tumours.

Sastre J, Paz-Ares L, Carcas A, Alfonso R, Grávalos C, Frías J, Guerra P, Pronk L, Cortés-Funes H, Díaz-Rubio E.

Cancer Chemother Pharmacol. 2005 May;55(5):453-60. Epub 2004 Oct 26.

PMID:
15818508
8.

Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study.

Pozzo C, Barone C, Szanto J, Padi E, Peschel C, Bükki J, Gorbunova V, Valvere V, Zaluski J, Biakhov M, Zuber E, Jacques C, Bugat R.

Ann Oncol. 2004 Dec;15(12):1773-81.

PMID:
15550582
9.

Phase 1/11 study of bi-weekly irinotecan plus cisplatin in the treatment of advanced gastric cancer.

Koizumi W, Kurihara M, Satoh A, Takiuchi H, Tanabe S, Shimada K, Iwasaki R, Saigenji K.

Anticancer Res. 2005 Mar-Apr;25(2B):1257-62.

10.

Phase I dose-escalating study of 24-h continuous infusion of 5-fluorouracil in combination with weekly docetaxel and cisplatin in patients with advanced gastric cancer.

Wang B, Zhang W, Hong X, Guo Y, Li J.

Cancer Chemother Pharmacol. 2009 Jan;63(2):213-8. doi: 10.1007/s00280-008-0728-4. Epub 2008 Mar 15.

PMID:
18343924
11.

Two phase I studies of concurrent radiation therapy with continuous-infusion 5-fluorouracil plus epirubicin, and either cisplatin or irinotecan for locally advanced upper gastrointestinal adenocarcinomas.

Sun W, Metz JM, Gallagher M, O'Dwyer PJ, Giantonio B, Whittington R, Haller DG.

Cancer Chemother Pharmacol. 2011 Mar;67(3):621-7. doi: 10.1007/s00280-010-1365-2. Epub 2010 May 22.

PMID:
20495918
12.

Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors.

Goetz MP, Erlichman C, Windebank AJ, Reid JM, Sloan JA, Atherton P, Adjei AA, Rubin J, Pitot H, Galanis E, Ames MM, Goldberg RM.

J Clin Oncol. 2003 Oct 15;21(20):3761-9. Epub 2003 Sep 8.

PMID:
12963697
13.

Phase I trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancer.

Tew WP, Radovich D, O'Reilly E, Schwartz G, Schrag D, Saltz LB, Kelsen DP, Kepler S, Ilson DH.

Invest New Drugs. 2009 Aug;27(4):366-73. doi: 10.1007/s10637-008-9194-4. Epub 2008 Oct 28.

15.

A phase I and II study of 2-weekly irinotecan with capecitabine in advanced gastroesophageal adenocarcinoma.

Burge ME, Smith D, Topham C, Jackson DP, Anthoney DA, Halstead F, Seymour MT.

Br J Cancer. 2006 May 8;94(9):1281-6.

16.

A novel combination of cisplatin, irinotecan, and capecitabine in patients with advanced cancer.

Jefford M, Michael M, Rosenthal MA, Davis ID, Green M, McClure B, Smith J, Waite B, Zalcberg J.

Invest New Drugs. 2004 Apr;22(2):185-92.

PMID:
14739668
17.

Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer.

Ilson DH.

Oncology (Williston Park). 2004 Dec;18(14 Suppl 14):22-5.

18.

A phase I study of sequential irinotecan and 5-fluorouracil/leucovorin.

Goldberg RM, Kaufmann SH, Atherton P, Sloan JA, Adjei AA, Pitot HC, Alberts SR, Rubin J, Miller LL, Erlichman C.

Ann Oncol. 2002 Oct;13(10):1674-80.

PMID:
12377659
19.

Phase I dose escalation trial of weekly docetaxel plus irinotecan in patients with advanced cancer.

Bleickardt E, Argiris A, Rich R, Blum K, McKeon A, Tara H, Zelterman D, Burtness B, Davies MJ, Murren JR.

Cancer Biol Ther. 2002 Nov-Dec;1(6):646-51. Review.

PMID:
12642688
20.

Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer.

Kim ST, Kang WK, Kang JH, Park KW, Lee J, Lee SH, Park JO, Kim K, Kim WS, Jung CW, Park YS, Im YH, Park K.

Br J Cancer. 2005 May 23;92(10):1850-4.

Supplemental Content

Support Center